HCW Biologics Inc. filed a Form D with the Securities and Exchange Commission on 2026-10-08.
HCW Biologics Inc. filed a Form D notice of an exempt securities offering with the SEC on October 8, 2026. The filing reports $1.50M sold. Its industry group is Biotechnology. It names Hing Wong (Executive Officer, Director), Rebecca Byam (Executive Officer), Peter Rhode (Executive Officer) (SEC Form D, October 8, 2026).
Sell to companies like HCW Biologics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-10-08 · the record
Pitching, partnering or investing alongside them? See who really runs and owns HCW Biologics Inc.
Free to see. No signup.
More on the people and the money behind HCW Biologics Inc., from the filings we hold.
Biotechnology raises by companies based in Florida, filed in October 2026, largest first.
Get an email when HCW Biologics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when HCW Biologics Inc. raises, hires or launches. No email unless you switch it on.
Watch HCW Biologics Inc. →Get the full cited report on HCW Biologics Inc.
What the filing shows about HCW Biologics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on HCW Biologics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for HCW Biologics Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $1.50M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
The Investor Relations website contains information about HCW Biologics, Inc.'s business for stockholders, potential investors, and financial analysts.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Hing Wong is named as Executive Officer and Director on the Form D that HCW Biologics Inc. filed with the SEC on 8 October 2026, one of 7 people that filing names.
Rebecca Byam is named as Executive Officer on the Form D that HCW Biologics Inc. filed with the SEC on 8 October 2026, one of 7 people that filing names.
Peter Rhode is named as Executive Officer on the Form D that HCW Biologics Inc. filed with the SEC on 8 October 2026, one of 7 people that filing names.
Scott Garrett is named as Director on the Form D that HCW Biologics Inc. filed with the SEC on 8 October 2026, one of 7 people that filing names.
Rick Greene is named as Director on the Form D that HCW Biologics Inc. filed with the SEC on 8 October 2026, one of 7 people that filing names.
Lisa Giles is named as Director on the Form D that HCW Biologics Inc. filed with the SEC on 8 October 2026, one of 7 people that filing names.
Lee Flowers is named as Executive Officer on the Form D that HCW Biologics Inc. filed with the SEC on 8 October 2026, one of 7 people that filing names.
7 people named on the filing — 4 holding an executive role and 3 as directors only.
Named as of the 2026-10-08 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about HCW Biologics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on HCW Biologics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on HCW Biologics Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist HCW Biologics Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind HCW Biologics Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-10-09 (investors.hcwbiologics.com).
Each opens in a new tab, filled in for HCW Biologics Inc.. With no account yet, you sign up free and land on the result.
On these lists: The rest of the US raises, week of 2026-10-05 · Biotech raises, week of 2026-10-05
https://mentionfox.com/funding/hcw-biologics-inc-form-d-000006